Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,219
datasets available to search
ShareScore release 0.9.0
Dataset results
1,219 results for “randomisation”
HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho
<p>These are pseudo-anonymised data from the HOSENG randomized trial: " HOSENG trial – HOme-based oral SElf-testiNG for absent and refusing individuals during a door-to-door HIV testing campaign: a cluster randomised clinical trial in rural Lesotho". The data dictionary explains the data available in the dataset. Between July 2018 and December 2018, 10516 eligible individuals from 106 consenting villages were enrolled from two districts of Lesotho, and followed up for a maximum of 120 days. Main manuscript reference, DOI: <a href="https://doi.org/10.1016/s2352-3018(20)30233-2">10.1016/S2352-3018(20)30233-2. </a>The protocol was published, DOI:10.1186/s13063-019-3469-2.</p>
Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomised clinical trial
<p>These are pseudo-anonymised data from the VIBRA randomized trial: "Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomised clinical trial". The data dictionary explains the data available in the dataset. Between August 2018 and May 2019, 257 eligible individuals from 117 consenting villages were enrolled from two districts of Lesotho, and followed up for a maximum of 15 months. The protocol was published, doi: 10.1186/s13063-019-3510-5</p>
Dataset Treatment of early childhood caries with three different topical fluoride treatments: a randomised clinical trial
<p>These files contain the data and the research script about the effectiveness of the 38% silver diamine fluoride (SDF, SDI Riva Star) and Tiefenfluorid (TF, Humanchemie GmbH), using two different application protocols in children ≤71 months of age with early childhood caries, with a focus on patient-centred outcomes including major complications (pain, abscess, extraction) and minor complications (lesion progression).</p> <p>This work was funded by European Regional Development Fund Postdoc Latvia 1.1.1.2/VIAA/3/19/543, Contract No 9.-14.5/27. Uribe was supported by European Union’s Horizon 2020 grant agreement 857287 for the Baltic Biomaterials Centre of Excellence.</p>
MiRoR7-P1- Disagreements in risk of bias assessment for randomised controlled trials included in more than one Cochrane systematic reviews: a research on research study using cross-sectional design
<p>dataset referring to </p> <p><strong>Disagreements in risk of bias assessment for randomised controlled trials included in more than one Cochrane systematic reviews: a research on research study using cross-sectional design</strong></p> <p> </p> <p> </p> <p>Lorenzo Bertizzolo<sup>1</sup>, Patrick M Bossuyt<sup>2</sup>, Ignacio Atal<sup>1, 5</sup>, Philippe Ravaud<sup>1, 3-6</sup>, Agnès Dechartres<sup>7</sup></p> <p> </p> <p><sup>1</sup> INSERM, U1153 Epidemiology and Biostatistics Sorbonne Paris Cité Research Center (CRESS), Methods of therapeutic evaluation of chronic diseases Team (METHODS), Paris, F-75004 France; Paris Descartes University, Sorbonne Paris Cité, France.</p> <p><sup>2</sup> Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Netherlands.</p> <p><sup>3</sup> Centre d’Épidémiologie Clinique, Hôpital Hôtel Dieu, AP-HP (Assistance Publique des Hôpitaux de Paris), Paris, France.</p> <p><sup>4</sup> Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</p> <p><sup>5</sup> Cochrane France, Paris, France</p> <p><sup>6</sup> Columbia University, Mailman School of Public Health, Department of Epidemiology, New York, USA</p> <p><sup>7</sup> Sorbonne Université, INSERM, Institut Pierre Louis de Santé Publique, Département Biostatistique, Santé Publique et Information Médicale, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière – Charles Foix, Paris, France</p>
Data relating to Clyne et al. Quality, scope and reporting standards of randomised controlled trials in Irish Health Research: an observational study
<p>Data relating to the study reported in the paper "Quality, scope and reporting standards of randomised controlled trials in Irish Health Research: an observational study".</p>
Supplementary file 30 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 30: Proportion of participants on methylphenidate with asthenia and fatigue </p>
Supplementary file 37 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 37: Proportion of participants on methylphenidate with restlessness and agitation</p>
Supplementary file 66 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 66: Proportion of participants on methylphenidate with gastrointestinal adverse events</p>
Supplementary file 55 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 55: Proportion of participants on methylphenidate with upper respiratory tract infection</p>
Supplementary file 11 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 11: Proportion of participants on methylphenidate with respiratory, thoracic and mediastinal disorders</p>
Supplementary file 22 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 22: Proportion of participants on methylphenidate with difficulty falling asleep</p>
Supplementary file 33 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 33: Proportion of participants on methylphenidate with involuntary movements </p>
Supplementary file 41 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 41: Proportion of participants on methylphenidate with taciturnity (‘talking too little’)</p>
Supplementary file 32 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 32 Proportion of participants on methylphenidate with increased need to sleep</p>
Supplementary file 44 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 44: Proportion of participants on methylphenidate with ’zombie-like’ demeanour</p>
Supplementary file 43 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 43: Proportion of participants on methylphenidate with isolation and lack of interest in others</p>
Data and analysis supplement for: Functional imagery training versus motivational interviewing for weight loss: a randomised controlled trial of brief individual interventions for overweight and obesity.
<p>This submission provides the data and code for analyses reported in our publication.</p>
DATASET OF "Impact of short-acting vs. standard anaesthetic agents on obstructive sleep apnoea: a randomised, controlled, triple-blind trial"
<p>Sleep apnoea is associated with negative outcomes following general anaesthesia. Current recommendations suggest using short-acting anaesthetic agents in preference to standard agents to reduce this risk, but there is currently no evidence to support this. This randomised controlled triple-blind trial tested the hypothesis that a combination of short-acting agents (desflurane-remifentanil) would reduce the postoperative impact of general anaesthesia on sleep apnoea severity compared with standard agents (sevoflurane-fentanyl). Sixty patients undergoing hip arthroplasty under general anaesthesia were randomised to anaesthesia with desflurane-remifentanil or sevoflurane-fentanyl. Respiratory polygraphy was performed before surgery and on the first and third postoperative nights. The primary outcome was the supine apnoea-hypopnoea index on the first postoperative night. Secondary outcomes were the supine apnoea-hypopnoea index on the third postoperative night, and the oxygen desaturation index on the first and third postoperative nights. Additional outcomes included intravenous morphine equivalent consumption and pain scores on postoperative days 1, 2 and 3. Pre-operative sleep study data were similar between groups. Mean (95%CI) values for the supine apnoea-hypopnoea index on the first postoperative night were 18.9 (12.7–25.0) and 21.4 (14.2–28.7) events.h<sup>-1</sup>, respectively, in the short-acting and standard anaesthesia groups (p=0.64). Corresponding values on the third postoperative night were 28.1 (15.8–40.3) and 38.0 (18.3–57.6) events.h<sup>-1</sup> (p=0.34). Secondary sleep- and pain-related outcomes were generally similar in the two groups. In conclusion, short-acting anaesthetic agents did not reduce the impact of general anaesthesia on sleep apnoea severity compared with standard agents. These data should prompt an update of current recommendations.</p>
Bevacizumab plus erlotinib versus erlotinib alone as first line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. BEVacizumab plus ERLotinib studY (BEVERLY): an academic, multicenter, randomised phase III trial.
<p>Background. Adding bevacizumab to erlotinib prolonged PFS of patients with EGFR-mutated advanced NSCLC in the Japanese NEJ026 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomized phase III trial of bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of advanced EGFR-mutated NSCLC.</p> <p>Methods. Eligible patients were randomized 1:1 to erlotinib (150mg daily) plus bevacizumab (15mg/kg iv q3w) or erlotinib alone, until disease progression or unacceptable toxicity. Center, ECOG PS and type of mutation (ex19 deletion vs ex21 L858R vs others) were stratification variables. Investigator-assessed PFS (IA-PFS) and blinded-independent centrally-reviewed PFS (BICR-PFS) were co-primary endpoints. With 80% power in detecting a 0·60 HR and 2–sided α error 0·05, 126 events out of 160 patients were needed. The trial was registered as NCT02633189 and EudraCT 2015-002235-17.</p> <p>Findings. From Apr 11, 2016 to Feb 27, 2019, 160 pts were randomized to erlotinib pus bevacizumab (80) or erlotinib alone (80). Baseline characteristics were balanced between arms; 34 (42·5%) patients in erlotinib plus bevacizumab arm and 43 (53·8%) in erlotinib arm were former or current smokers. At a median follow-up of 36·3 months, 140 PFS events (87·5%) were reported, 68 with erlotinib plus bevacizumab and 72 with erlotinib. Median IA-PFS was 15·4 months (95% CI 12·2–18·6) with erlotinib plus bevacizumab and 9·6 months (95% CI 8·2–10·6) with erlotinib (HR 0·66; 95%CI: 0·47–0·92). BICR-PFS analysis confirmed this result. A significant interaction with treatment effect was found for smoking habit (P=0·0323): former or current smokers receiving erlotinib plus bevacizumab had a longer PFS (16·9 months [95% CI 10·2–21·8] versus 8·8 months [95% CI 5·6–9·6]) than those receiving erlotinib alone.</p> <p>Hypertension (grade≥3: 24% vs 5%), skin rash (grade≥3: 31% vs 14%), thromboembolic events (any grade: 11% vs 4%), and proteinuria (any grade: 23% vs 6%) were more frequent with the combination treatment.</p> <p>Interpretation. The addition of bevacizumab to first-line erlotinib significantly prolonged PFS in Italian patients with EGFR-mutated NSCLC, without unexpected safety issues.</p>
Dataset supplementing the article A randomised controlled trial of Losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
<p>These data supplement the article A randomised controlled trial of Losartan as an antifibrotic agent in non-alcoholic steatohepatitis.</p> <p>Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair Burt, Elaine McColl, Deborah D. Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury5, Derek Mann, Quentin M. Anstee, Christopher P. Day.</p> <p>Use is free for academic purposes, provided the aforementioned article is appropriately cited.</p> <p>The data consists of anonymised csv data files, described in DataDictionaryFELINE.csv, the final protocol and a blank copy of the case report forms used (both pdf).</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.